Skip to main content
. 2022 Mar 15;82(6):1013–1024. doi: 10.1158/0008-5472.CAN-21-1707

Figure 6.

Figure 6. Inhibition of CTPS1 sensitizes MYC-driven cancer cells to BAY-1895344. A and B, HCT116 (A) and RKO (B) cells expressing CTPS1 and CTPS2 shRNA alone or together were treated with BAY-1895344 for 48 hours, followed by apoptosis analysis. C, Apoptosis analysis of WT, CTPS1−/−, CTPS2−/−, and CTPS1/2−/− RKO cells treated with BAY-1895344 for 48 hours. D–F, Immunoblots of p-Chk1 in HCT116 and RKO cells from A, B, and C. G–J, Pearson correlation analysis of the mRNA expressions of MYC and CTPS1 (G), CTPS2 (H), CAD (I), or PPAT (J) across 33 types of cancer. K, Immunoblots of the indicated proteins in ARPE-19-MYC (DOX+) and ARPE-19-MYC (DOX−) cells. L and M, Immunoblots of the indicated proteins in RKO (L) and HCT116 (M) cells expressing control or MYC shRNA. Graphic data are means ± SEM; n = 3. *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001. NS, not significant; ctrl, control; DOX, doxycycline.

Inhibition of CTPS1 sensitizes MYC-driven cancer cells to BAY-1895344. A and B, HCT116 (A) and RKO (B) cells expressing CTPS1 and CTPS2 shRNA alone or together were treated with BAY-1895344 for 48 hours, followed by apoptosis analysis. C, Apoptosis analysis of WT, CTPS1−/−, CTPS2−/−, and CTPS1/2−/− RKO cells treated with BAY-1895344 for 48 hours. D–F, Immunoblots of p-Chk1 in HCT116 and RKO cells from A, B, and C. G–J, Pearson correlation analysis of the mRNA expressions of MYC and CTPS1 (G), CTPS2 (H), CAD (I), or PPAT (J) across 33 types of cancer. K, Immunoblots of the indicated proteins in ARPE-19-MYC (DOX+) and ARPE-19-MYC (DOX−) cells. L and M, Immunoblots of the indicated proteins in RKO (L) and HCT116 (M) cells expressing control or MYC shRNA. Graphic data are means ± SEM; n = 3. *, P < 0.05; **, P < 0.01; ***, P < 0.001; #, P < 0.0001. NS, not significant; ctrl, control; DOX, doxycycline.